Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Bavencio Drug Analysis 2018: A Fully Human MAb Targeting the PD-L1 Protein - ResearchAndMarkets.com

Research and Markets
Posted on: 21 Feb 18

The "Drug Analysis: Bavencio" drug pipelines has been added to ResearchAndMarkets.com's offering.

Bavencio is a fully human MAb targeting the PD-L1 protein. The interaction between PD-L1 and its receptor, programmed death-1 (PD-1), regulates complex signaling pathways that affect T-cell activation, proliferation, and survival, and can induce apoptosis of tumor-specific T cells (Keir et al., 2008; Zhang et al., 2009; Zitvogel and Kroemer, 2012). By inhibiting the PD-1/PD-L1 interaction, Bavencio reduces the ability of the tumor to evade immune system targeting, and enables the activation of T cells and the adaptive immune system (Avelumab fact sheet, 2015; Pardoll, 2012).

In addition, preclinical and clinical studies have suggested that drugs targeting the PD-1/PD-L1 pathway may have fewer side effects than other immune checkpoint inhibitors (Raufi and Klempner, 2015; Brahmer et al., 2012).

Product Profiles

  • Bavencio: Head and neck cancer
  • Bavencio: Ovarian cancer
  • Bavencio: Bladder cancer
  • avelumab: Renal cell cancer (RCC)
  • avelumab: Non-small cell lung cancer (NSCLC)
  • avelumab: Gastric cancer

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/pkfqsh/bavencio_drug?w=4

View source version on businesswire.com: http://www.businesswire.com/news/home/20180221006151/en/

Business Wire
www.businesswire.com

Last updated on: 21/02/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.